<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368930">
  <stage>Registered</stage>
  <submitdate>14/07/2015</submitdate>
  <approvaldate>12/10/2015</approvaldate>
  <actrnumber>ACTRN12615001059550</actrnumber>
  <trial_identification>
    <studytitle>A Within-Subject Single Dose Trial on the Effects of Bremelanotide on Social Cognition and Behaviour</studytitle>
    <scientifictitle>Do Males Age 16 Years and Older with Autism Spectrum Disorders show an effect of Bremelanotide on Social Cognition and Behaviour?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil unknown</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Autism Spectrum Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Autistic spectrum disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants receive both treatments in a random order. Participants are randomised to receive either a single dose subcutaneous injection of 1.75mg of PT-141 or Placebo, followed by a two week wash-out period and then a single dose subcutaneous injection of 1.75mg of PT-141 or placebo. Participants will have exposure to the PT-141 drug within the research premises here in the Brain and Mind Centre, University of Sydney. They are not allowed to go outside the research premises while the drug is active, which will take 45 minutes from drug administration.</interventions>
    <comparator>Single dose subcutaneous injection of 1.75mg of placebo. The placebo is composed of 2.5% (w/v) glycerin (United States Pharmacopoeia [USP], mutli-compendial, vegetable-grade) in sterile water for injection, USP, adjusted to pH 5.0 with either hydrochloric acid or sodium hydroxide as necessary.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Correct recognition performance in reading emotions from  faces as assess by the eye/faces test</outcome>
      <timepoint>45 minutes after each single dose administration</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Amount of eye gaze to the eyes of faces using Tobi eye tracker </outcome>
      <timepoint>45 minutes after each single dose administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Correct response to inclusion and exclusion toward other players using the 'Social Ball-tossing Game' task.</outcome>
      <timepoint>45 minutes after each single dose administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Degree of Heart Rate Variability as assess by physiological recording of heart-rate</outcome>
      <timepoint>45 post drug administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correct performance in reading emotion from scenes using movie still task</outcome>
      <timepoint>45 minutes post each single dose administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Performance of speed of emotion valence recognition in words using speeded word recognition task comparing social, sexual and control words </outcome>
      <timepoint>45 minutes post administration</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Participants must meet DSM-IV-TR criteria for Autistic Disorder, Pervasive Developmental Disorder-Not Otherwise Specified or Aspergers Disorder.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Clinical participants will be excluded if they meet the following exclusion criteria: 

Severe depression with suicidal thought/and or actions, High blood pressure, Severe cardiovascular problems, Kidney disease, Psychosis, Addiction to nicotine and/or illicit substances.

Concomitant medications that exclude participants: use of
phosphodiesterase type 5 inhibitor (e.g., erectile dysfunction) medications.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants are assigned to sequential treatment packs labelled with a unique study number. Neither participants nor research staff will be aware of the group allocation.</concealment>
    <sequence>Allocation follows a computer-generated randomisation schedule with balanced variable blocks, prepared by the pharmacist. Each re-packed treatment contains one active and one identical and matched subcutaneous injection. The pharmacist will hold the randomisation code.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>13/10/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>4/09/2016</anticipatedenddate>
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2046 - Abbotsford</postcode>
    <postcode>2131 - Ashfield</postcode>
    <postcode>2041 - Balmain</postcode>
    <postcode>2137 - North Strathfield</postcode>
    <postcode>2132 - Croydon</postcode>
    <postcode>2042 - Newtown</postcode>
    <postcode>2040 - Leichhardt</postcode>
    <postcode>2045 - Haberfield</postcode>
    <postcode>2204 - Marrickville</postcode>
    <postcode>2130 - Summer Hill</postcode>
    <postcode>2007 - Broadway</postcode>
    <postcode>2560 - Campbelltown</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>The University of Sydney, College Street, University of Sydney, NSW
2006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Simons Foundations</fundingname>
      <fundingaddress>Simons Foundation
160 Fifth Avenue, 7th Floor
New York, NY 10010</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this proposal is to conduct the first study of the impact of subcutaneous administration of PT-141 on key mechanisms involved in social communication in adults with
autism. We hypothesize that PT-141 will, in comparison to an identical and matched placebo: increase gaze duration and fixations to key face regions, improve accuracy and the speed of identification of facial emotion recognition, increase heart rate variability, and improve accuracy of response to social cues.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sydney</ethicname>
      <ethicaddress>The University of Sydney, Margaret Telfer Building (K07), University of
Sydney, NSW 2006</ethicaddress>
      <ethicapprovaldate>28/11/2013</ethicapprovaldate>
      <hrec>2012/2816</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Adam Guastella</name>
      <address>Brain and Mind Research Institute, 100 Mallett Street, Camperdown, NSW
2050</address>
      <phone>+61 2 9351 0539</phone>
      <fax />
      <email>adam.guastella@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christine Yun Song</name>
      <address>Brain and Mind Research Institute, 94 Mallett Street, Camperdown, NSW
2050</address>
      <phone>+61 2 9351 0940</phone>
      <fax />
      <email>yun.song@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Adam Guastella</name>
      <address>Brain and Mind Research Institute, 100 Mallett Street, Camperdown, NSW
2050</address>
      <phone>+61 2 9351 0539</phone>
      <fax />
      <email>adam.guastella@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Tiffany Russel Sia</name>
      <address>Brain and Mind Research Institute, 94 Mallett Street, Camperdown, NSW
2050</address>
      <phone>+61 2 91144 230</phone>
      <fax />
      <email>tiffany.sia@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>